Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Taiho Oncology is the lead sponsor of 14 current clinical trials in our USA, UK, China and EU (CTIS) registers. 6 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Decitabine and Cedazuridine, Zipalertinib and Futibatinib. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Recruiting646%
Active, closed646%
By invitation18%

Trials by phase

Phase 2431%
Phase 1323%
Phase 2/3215%
Phase 1/2215%
Phase 3215%

Clinical trials sponsored by Taiho Oncology

13 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) NCT04256317 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm Drugs: Azacitidine, Venetoclax	Phase 2/3	Recruiting	2020-05	UK, USA
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Drug: Zipalertinib	Phase 2	Recruiting	2023-07	UK, USA
A Study of ARC-02 in B-cell NHL NCT07691606 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma Drug: Rituximab	Phase 1	Recruiting	2026-06	USA
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement NCT05727176 · ClinicalTrials.gov ↗ · Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Drug: Futibatinib	Phase 2	Recruiting	2023-07	USA, China
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment NCT04953897 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drug: Decitabine and Cedazuridine	Phase 1	Recruiting	2021-12	USA
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment NCT04953910 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drug: Decitabine and Cedazuridine	Phase 1	Recruiting	2022-12	USA
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) NCT04093570 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes Drug: Decitabine and Cedazuridine	Phase 2	By invitation	2019-09	USA
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. NCT06506955 · Advanced/Metastatic Cancer Drug: Futibatinib	Phase 2/3	Active, closed	2024-10	UK, USA
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas NCT02503423 · ClinicalTrials.gov ↗ · Solid Tumors, Lymphoma	Phase 1/2	Active, closed	2015-07	UK, USA
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection NCT07128199 · ClinicalTrials.gov ↗ · Lung Cancer, Adjuvant, Post-surgical Drug: Zipalertinib	Phase 3	Active, closed	2025-12	UK, USA
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) NCT05973773 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Drug: Zipalertinib	Phase 3	Active, closed	2023-12	UK, USA
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer Drugs: Cisplatin, Futibatinib, Irinotecan	Phase 2	Active, closed	2023-07	USA
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) NCT04657081 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Decitabine and Cedazuridine, Venetoclax	Phase 1/2	Active, closed	2021-02	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Taiho Oncology in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Taiho Oncology as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4) 2025-521775-31-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Cisplatin, Zipalertinib	Phase 3	Ongoing	Germany, Poland, Spain + 6 more

Drugs in Taiho Oncology trials

14 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Decitabine and Cedazuridine4 Zipalertinib4 Futibatinib3 Cisplatin2 Venetoclax2 Azacitidine1 Carboplatin1 Irinotecan1 Ivonescimab1 Leucovorin1 Levoleucovorin1 Oxaliplatin1 Pembrolizumab1 Rituximab1

Conditions in Taiho Oncology trials

21 conditions

Acute Myeloid Leukemia5 Myelodysplastic Syndromes4Chronic Myelomonocytic Leukemia2Advanced/Metastatic Cancer1Myelodysplastic Syndrome/Neoplasm1Solid Tumors1 Lymphoma1Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations1Lung Cancer1Adjuvant1Post-surgical1EGFR1Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation1B-cell Non Hodgkin Lymphoma1Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer1Esophageal Adenocarcinoma1Esophageal Squamous Cell Cancer1Siewert Type 1 GEJ Cancer1Advanced Cholangiocarcinoma1FGFR2 Fusions1Gene Rearrangement1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	13	6
Clinical trials in UK	6	2
Clinical trials in China	1	1
EU register (CTIS)	1	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
The First Affiliated Hospital of Soochow University	14
First Affiliated Hospital of Zhejiang University	6
Peking University People's Hospital	5
Zhejiang University	5
Shenzhen Geno-Immune Medical Institute	4
Stichting Hemato-Oncologie voor Volwassenen Nederland	3
Orca Biosystems	3
Shanghai Jiao Tong University School of Medicine	3
Kura Oncology	2
Shenzhen University General Hospital	2

Sponsors with the most current trials registered for this condition.

Questions about Taiho Oncology trials

How many clinical trials does Taiho Oncology sponsor?

Taiho Oncology is the lead sponsor of 13 current trials on ClinicalTrials.gov in our USA, UK and China registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Taiho Oncology trials recruiting?

Yes. 6 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Taiho Oncology testing?

Its current trials name 14 drugs and biologicals as interventions. The most frequent are Decitabine and Cedazuridine (4), Zipalertinib (4), Futibatinib (3), Cisplatin (2) and Venetoclax (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Taiho Oncology clinical trials